Condition: Bladder Cancer · Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Assess the safety and efficacy of 9MW2821 in patients with high-risk non-muscle-invasive bladder cancer (NMIBC) who have previously failed to intravesical therapy. Provide a new treatment option for patients with NMIBC recurrence, reduce the risk of tumor recurrence, decrease the rate of radical bladder surgery, and enhance the quality of life for patients.
This description comes directly from the study's public registry record.
Guo Hongqian, PhD · 8613605171690 · dr.ghq@nju.edu.cn
Always discuss trial participation with your own doctor first.
| The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Nanjing, Jiangsu, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06551233